AZD1402

Phase 2Small molecule

AstraZeneca

AZD1402 is one of 87 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusActive, not recruiting

ObesityActive, not recruiting

AsthmaActive, not recruiting

Type 2 Diabetes MellitusPhase 2

Active, not recruiting

ObesityPhase 1

Active, not recruiting

AsthmaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Singulair

AstraZeneca

Preclinical

17 2

Cinqair

Teva

Preclinical

13 3

AZD1402

AstraZeneca

Phase 2

1 4

Atrovent

Boehringer Ingelheim

Preclinical

5 5

Symbicort

AstraZeneca

Preclinical

6 6

Decadron

QQuince Therapeutics S.p.A.

Preclinical

1 7

Tylenol

KKenvue Brands

Preclinical

1 8

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 9

DUPIXENT

Regeneron

Preclinical

1 10

Paracetamol

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Asthma1 trial

Efficacy and Safety of Inhaled AZD1402 Administered for Four Weeks in Adults With Asthma on Medium-to-High Dose Inhaled Corticosteroids

Terminated· AstraZeneca logo

AstraZeneca·Phase 2·NCT04643158·72 enrolled

Tics1 trial

Study to Assess Effect of Device and Formulation on Pharmacokinetics (PK) of AZD1402

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT03921268·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for AZD1402. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD1402 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD1402. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AstraZeneca

AZD1402

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Asthma1 trial

Tics1 trial

References

Drug Info

Quick Facts

Related News